Clinical Trial: Camrelizumab (a PD-1 inhibitor) in Combination with S-1 or Capecitabine for Adjuvant Therapy Following Curative Surgery for Biliary Tract Cancer (BTC) with High-Risk Factors: A Single-Center, Phase II Exploratory Clinical Study (China)

China, Sept. 10 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Camrelizumab (a PD-1 inhibitor) in Combination with S-1 or Capecitabine for Adjuvant Therapy Following Curative Surgery for Biliary Tract Cancer (BTC) with High-Risk Factors: A Single-Center, Phase II Exploratory Clinical Study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600132074

Registration Time: 2026/09/09

Type: Interventional study

Primary Sponsor: Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=342218

Published by HT Digital Content Servic...